MIAMI, March 15, 2021 /PRNewswire/ -- Cano Health
(the "Company"), a leading value-based primary care delivery
platform for seniors, today announced the formation of its Board of
Directors, consisting of seasoned professionals from across the
health care, technology and financial sectors.
Upon the closing of the business combination with Jaws
Acquisition Corp. (NYSE: JWS), the members of the Board of
Directors will include Dr. Marlow
Hernandez, Founder and CEO of Cano Health, alongside
Elliot Cooperstone, Dr. Lewis Gold, Jacqueline
Guichelaar, Angel Morales,
Dr. Alan Muney, Kim Rivera, Barry
Sternlicht, and Solomon
Trujillo. Dr. Marlow
Hernandez will serve as Chairman of the Board.
"I am pleased to welcome the members of our newly-formed Board
of Directors. As Cano Health prepares for its next stage of growth
as a publicly-traded company, the Board's diverse experience and
strategic expertise will be an invaluable asset to our management
team," said Dr. Hernandez. "I am humbled and honored to partner
with this outstanding group of professionals to continue to
transform healthcare in America."
Marlow Hernandez
Dr. Marlow Hernandez is the
Founder and Chief Executive Officer of Cano Health and will serve
as the Chairman of its Board of Directors. A native of Cuba, Dr. Hernandez immigrated to the U.S.
with his family in 1993. Driven by a lifelong calling to medicine,
he received a bachelor's degree in neuroscience from the
University of Miami, a medical degree
from Nova Southeastern University, and
completed his residency in internal medicine at Cleveland Clinic
Florida. He also received master's degrees in business
administration and public health, and is a fellow of the American
College of Physicians. Dr. Hernandez opened his first medical
center in 2010. He saw a need in his community for quality,
affordable healthcare, and developed an integrated primary care
model focused on improving clinical outcomes and decreasing costs.
From humble beginnings as a small practice in Pembroke Pines, Florida, Cano Health has grown
to more than 70 medical centers across Florida, Texas, and Nevada serving over 100,000 managed care
patients.
Elliot Cooperstone
Mr. Cooperstone is the Founder and Managing Partner of InTandem
Capital Partners, a leading private equity firm that invests in and
accelerates the growth of small to mid-sized companies in select
health care and insurance services sectors. Mr. Cooperstone was
previously CEO of Prodigy Health Group, a health care services
holding company acquired in 2011 by Aetna. Earlier in his
career, Mr. Cooperstone was General Manager of the Employer
Services Group at Intuit, a co-founder and CEO of
EmployeeMatters, and Executive Vice President and Chief
Administrative Officer of Alexander & Alexander Services,
Inc. He also had prior experience with Travelers Group, The
Walt Disney Company and The Boston Consulting
Group.
Lewis Gold
Dr. Gold is Co-Founder and Chairman of the Board at Advanced
Recovery Systems, an integrated behavioral health company
specializing in the treatment of substance abuse, eating disorders
and associated mental health issues. He also serves as
non-executive Chairman of Urology Management Associates and
Siromed. Previously, Dr. Gold co-founded Sheridan Healthcare in
1994 and served as its Executive Vice Chairman and on its Board of
Directors. Under his leadership, Sheridan Healthcare grew from a
single local practice to a national company in 23
states.
Jacqueline Guichelaar
Ms. Guichelaar is Senior Vice President and Group Chief
Information Officer at Cisco Systems, Inc. ("Cisco"), where she
oversees a multi-billion-dollar organization responsible
for transforming all of Cisco's business processes,
underpinned by technology platforms and a clear data strategy, with
the ultimate goal of maximizing the customer, partner and employee
experience. Prior to joining Cisco, she was the Group Chief
Information Officer at Thomson Reuters, where she led a technology
organization to deliver the company's digital strategy.
Throughout her career, including roles at Lloyds Bank,
Deutsche Bank, and IBM, Ms. Guichelaar has focused on the
transformation of companies by creating teams that move in tandem
with business expectations and the pace of the
industry. She is a board member of Covenant House in
California, a non-profit that
believes all young people deserve food, shelter, clothing,
education, and love.
Angel Morales
Mr. Morales is the Founder and CEO of Morales Capital, an
investment firm focused on private equity opportunities in
mission-oriented companies managed by Latinos and
other underrepresented groups. He has 25 years of
private equity experience, including as co-head of Bank of America
Merrill Lynch Capital Partners and as a co-Founder and Managing
Partner of North Cove Partners, an investment management firm with
a global portfolio and assets under management in excess of
$6 billion. He has served on the
Board of Directors for a number of public and private companies in
the United States and
abroad. Mr. Morales is active in education-related
philanthropy and serves as the Founding Board Chair of
Comp Sci High in the South Bronx
as well as on the Board of Directors of the Hispanic Scholarship
Fund and Transcend Education.
Alan Muney
Dr. Muney is currently a senior healthcare advisor for several
private investment funds and serves on the Board of Directors for
both Alcresta Therapeutics and KabaFusion. Previously, he served as
Cigna's Chief Medical Officer, responsible for clinical
strategy and policy, health advocacy programs, coverage policy, and
quality measurement and improvement, and as the Executive Vice
President of Total Health and Network, responsible for internal and
external clinical operations and nationally for provider
contracting and provider relations. Prior to Cigna, Dr. Muney was
an Executive Director in the Private Equity Group at The Blackstone
Group, and the CEO of Equity Healthcare, which he founded to manage
the healthcare costs of Blackstone's portfolio companies. He
previously served as Executive Vice President and Chief Medical
Officer of Oxford Health Plans, Chief Medical Officer of
UnitedHealthcare's Northeast region, Senior Vice President and
Chief Medical Officer for Avanti Health systems, and Regional
Medical Director for Mullikin Medical Centers
in California.
Kim Rivera
Ms. Rivera currently serves as a special advisor to the CEO of
HP, Inc. She is a seasoned public company executive with a
track record spanning technology, health care, and
consumer products. She has experience shaping and driving
business and go-to-market strategies, negotiating and
integrating major acquisitions, and navigating complex
corporate governance, compliance and
regulatory issues. Most recently, she was President,
Strategy and Business Management and Chief Legal Officer at
HP. During her tenure in this role she led corporate
strategy and business development, customer support, procurement,
real estate and workplace functions, as well as sales operations
and enterprise transformation. Ms. Rivera also led HP's
worldwide legal organization, including all aspects of legal,
governance, ethics and compliance, and government
affairs. Prior to joining HP, she served as the Chief Legal
Officer and Corporate Secretary for DaVita HealthCare Partners. Ms.
Rivera also held senior executive legal and compliance
positions at The Clorox Company and Rockwell
Automation. Ms. Rivera serves on the Thomson Reuters
Board of Directors, and is a member of their Audit and Risk
Committees.
Barry Sternlicht
Mr. Sternlicht is the Chairman of Jaws Acquisition Corp. Mr.
Sternlicht founded Starwood Capital, a private alternative
investment firm focused on global real estate, hotel management,
and energy infrastructure, in 1991, serving as Chairman and Chief
Executive Officer. Mr. Sternlicht currently serves as the Chairman
and Chief Executive Officer of Starwood Property Trust (NYSE:
STWD), a leading, diversified real estate finance company. Mr.
Sternlicht also has deep operating expertise, serving as the
Chairman, from January 1995 through
May 2005, and as the Chief Executive
Officer, from January 1995 through
September 2004, of Starwood Hotels
& Resorts Worldwide. Some of Mr. Sternlicht's other public
market experience includes serving as a Director of INVH, the
largest publicly-traded investor, owner and operator of
single-family homes in the U.S.; serving on the Board of Directors
of The Estée Lauder Companies, a multinational manufacturer and
marketer of prestige skincare, makeup, fragrance and hair care
products, since 2004; and serving as a Director of A.S.
Roma, the professional Italian
football club based in Rome, from
2014-2020.
Solomon Trujillo
Mr. Trujillo is a global business executive who has uniquely
served as CEO of three large market-cap global companies in the
three corridors of the world. He is known as a
transformative and innovative leader, recognized for his technology
and innovation leadership in communications, media, and technology.
Mr. Trujillo has served on the Board of Directors of globally
branded companies including PepsiCo, Bank of America, EDS, Orange,
Telstra, Gannett, US West, Target, Soufun (China), and WPP. He currently serves
on the Board of Directors of Western Union, a global financial
services company, and Encantos, an award-winning ed-tech company.
He served as a trade policy advisor to the Clinton and Bush
administrations and remains active in public policy issues related
to trade, productivity, innovation, and economic development. Mr.
Trujillo chairs the Trujillo Group, LLC, investing in private
companies domestically and internationally.
About Cano Health
Cano Health operates value-based primary care centers and
supports affiliated medical practices that specialize in primary
care for seniors in Florida,
Texas, Nevada, and Puerto
Rico, with additional markets in development. As part of its
care coordination strategy, Cano Health provides sophisticated,
high-touch population health management tools including telehealth,
prescription home delivery, wellness programs, transition of care,
and high-risk and complex care management.
The Company's personalized patient care and proactive approach
to wellness and preventive care sets it apart from competitors.
Cano Health has consistently improved clinical outcomes while
reducing costs, affording patients the opportunity to lead longer
and healthier lives. The Company was recognized in August 2020 by Inc. Magazine for the second
consecutive year as one of the fastest-growing health care
companies in the country, ranking 39th among all U.S. privately
held companies as part of its annual 5000 ranking. For more
information visit www.canohealth.com.
Additional Information
On November 11, 2020, Jaws
Acquisition Corp. ("Jaws") entered into a business combination
agreement (as it may be amended, supplemented or otherwise modified
from time to time, the "Business Combination Agreement" and the
transactions contemplated therein, the "Business Combination"), by
and among Jaws, Jaws Merger Sub, LLC, Primary Care (ITC) Holdings,
LLC and the Company.
In connection with the Business Combination, including the
domestication of Jaws as a Delaware corporation, Jaws filed with the
Securities and Exchange Commission (the "SEC") a registration
statement on Form S-4 containing a preliminary proxy statement and
a preliminary prospectus of Jaws, and after the registration
statement is declared effective, Jaws will mail a definitive proxy
statement/prospectus about the Business Combination to its
shareholders. This Current Report on Form 8-K does not contain all
the information that should be considered concerning the Business
Combination and is not intended to form the basis of any investment
decision or any other decision in respect of the Business
Combination. Jaws' shareholders and other interested persons are
advised to read the preliminary proxy statement/prospectus and,
when available, any amendments thereto, the definitive proxy
statement/prospectus and other documents filed in connection with
the Business Combination, as these materials will contain important
information about Jaws, the Company and the Business Combination.
When available, the definitive proxy statement/prospectus and other
relevant materials for the Business Combination will be mailed to
shareholders of Jaws as of the record date that was established for
voting on the Business Combination. Shareholders are able to obtain
copies of the preliminary proxy statement/prospectus and, once
available, the definitive proxy statement/prospectus and other
documents filed with the SEC, without charge, at the SEC's website
at www.sec.gov, or by directing a request to: 1601 Washington
Avenue, Suite 800, Miami Beach, FL
33139.
Participants in the Solicitation
Jaws and its directors and executive officers may be deemed
participants in the solicitation of proxies from Jaws' shareholders
with respect to the Business Combination. A list of the names of
those directors and executive officers and a description of their
interests in Jaws is contained in Jaws' final prospectus related to
its initial public offering, dated April 28,
2020, which was filed with the SEC and is available free of
charge at the SEC's website at www.sec.gov, or by directing a
request to Jaws Acquisition Corp., 1601 Washington Avenue, Suite
800, Miami Beach, FL 33139.
Additional information regarding the interests of such participants
will be contained in the definitive proxy statement/prospectus for
the Business Combination when available.
The Company and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
shareholders of Jaws in connection with the Business Combination. A
list of the names of such directors and executive officers and
information regarding their interests in the Business Combination
will be included in the definitive proxy statement/prospectus for
the Business Combination when available.
No Offer or Solicitation
This communication is not a proxy statement or solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the potential transaction and shall not constitute an
offer to sell or a solicitation of an offer to buy the securities
of Jaws or the Company, nor shall there be any sale of any such
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction. No offer of securities shall be made except by means
of a prospectus meeting the requirements of the Securities Act.
Forward-Looking Statements
Certain statements in this Current Report on Form 8-K may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Jaws' or the Company's future
financial or operating performance. For example, projections of
future growth, financial performance, and other metrics are
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "should,"
"expect," "intend," "will," "estimate," "anticipate," "believe,"
"predict," "potential" or "continue," or the negatives of these
terms or variations of them or similar terminology. Such
forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward looking
statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Jaws and its
management, and the Company and its management, as the case may be,
are inherently uncertain. Factors that may cause actual results to
differ materially from current expectations include, but are not
limited to: (1) the occurrence of any event, change or other
circumstances that could give rise to the termination of
negotiations and any subsequent definitive agreements with respect
to the Business Combination; (2) the outcome of any legal
proceedings that may be instituted against Jaws, the combined
company or others following the announcement of the Business
Combination and any definitive agreements with respect thereto; (3)
the inability to complete the Business Combination due to the
failure to obtain approval of the shareholders of Jaws, to obtain
financing to complete the Business Combination or to satisfy other
conditions to closing; (4) changes to the proposed structure of the
Business Combination that may be required or appropriate as a
result of applicable laws or regulations or as a condition to
obtaining regulatory approval of the Business Combination; (5) the
ability to meet stock exchange listing standards following the
consummation of the Business Combination; (6) the risk that the
Business Combination disrupts current plans and operations of the
Company as a result of the announcement and consummation of the
Business Combination; (7) the ability to recognize the anticipated
benefits of the Business Combination, which may be affected by,
among other things, competition, the ability of the combined
company to grow and manage growth profitably, maintain
relationships with customers and suppliers and retain its
management and key employees; (8) costs related to the Business
Combination; (9) changes in applicable laws or regulations; (10)
the possibility that the Company or the combined company may be
adversely affected by other economic, business, and/or competitive
factors; (11) the Company's estimates of expenses and
profitability; and (12) other risks and uncertainties set forth in
the section entitled "Risk Factors" and "Cautionary Note Regarding
Forward-Looking Statements" in Jaws' final prospectus relating to
its initial public offering, dated April 28,
2020.
Nothing in this Current Report on Form 8-K should be regarded as
a representation by any person that the forward-looking statements
set forth herein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You
should not place undue reliance on forward-looking statements,
which speak only as of the date they are made. Neither Jaws nor the
Company undertakes any duty to update these forward-looking
statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cano-health-announces-the-formation-of-its-board-of-directors-301247363.html
SOURCE Cano Health, LLC